Cargando…
Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a furt...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918293/ https://www.ncbi.nlm.nih.gov/pubmed/27508202 http://dx.doi.org/10.2147/JHC.S81309 |
_version_ | 1782439097735839744 |
---|---|
author | Abdel-Wahab, Reham Shehata, Samir Hassan, Manal M Habra, Mouhammed A Eskandari, Ghazaleh Tinkey, Peggy T Mitchell, Jennifer Lee, Ju-Seog Amin, Hesham M Kaseb, Ahmed O |
author_facet | Abdel-Wahab, Reham Shehata, Samir Hassan, Manal M Habra, Mouhammed A Eskandari, Ghazaleh Tinkey, Peggy T Mitchell, Jennifer Lee, Ju-Seog Amin, Hesham M Kaseb, Ahmed O |
author_sort | Abdel-Wahab, Reham |
collection | PubMed |
description | Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child–Turcotte–Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials. |
format | Online Article Text |
id | pubmed-4918293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49182932016-08-09 Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma Abdel-Wahab, Reham Shehata, Samir Hassan, Manal M Habra, Mouhammed A Eskandari, Ghazaleh Tinkey, Peggy T Mitchell, Jennifer Lee, Ju-Seog Amin, Hesham M Kaseb, Ahmed O J Hepatocell Carcinoma Review Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child–Turcotte–Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials. Dove Medical Press 2015-09-18 /pmc/articles/PMC4918293/ /pubmed/27508202 http://dx.doi.org/10.2147/JHC.S81309 Text en © 2015 Abdel-Wahab et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Abdel-Wahab, Reham Shehata, Samir Hassan, Manal M Habra, Mouhammed A Eskandari, Ghazaleh Tinkey, Peggy T Mitchell, Jennifer Lee, Ju-Seog Amin, Hesham M Kaseb, Ahmed O Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
title | Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
title_full | Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
title_fullStr | Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
title_full_unstemmed | Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
title_short | Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
title_sort | type i insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918293/ https://www.ncbi.nlm.nih.gov/pubmed/27508202 http://dx.doi.org/10.2147/JHC.S81309 |
work_keys_str_mv | AT abdelwahabreham typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT shehatasamir typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT hassanmanalm typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT habramouhammeda typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT eskandarighazaleh typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT tinkeypeggyt typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT mitchelljennifer typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT leejuseog typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT aminheshamm typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma AT kasebahmedo typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma |